BAUDETTE, Minn., Sept. 11, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Vancomycin HCl for Oral Solution, 250mg per 5mL (the generic equivalent ...

Oral Vancomycin Solution Kit Launched CutisPharma announced the launch of FIRST Vancomycin oral solution compounding kits for the treatment of Clostridium difficile (C.diff) infection. CutisPharma ...

Amneal is voluntarily recalling four lots of Vancomycin Hydrochloride for Oral Solution, 250 mg/5 mL packaged in 80 mL, 150 mL or 300 mL pack sizes, to the consumer level. Some bottles may have been ...

Vancomycin is indicated to treat enterocolitis caused by Staphylococcus aureus and antibiotic-associated pseudomembranous colitis caused by C. difficile. ANI Pharmaceuticals announced that the Food ...

WILMINGTON, Mass., April 2, 2018 /PRNewswire/ -- CutisPharma announced today the commercial launch of FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile ...

Wilmington, MA, Azurity Pharmaceuticals, Inc. (“Azurity”) is voluntarily recalling one lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit (“Firvanq®”) to the ...

Amneal Pharmaceuticals, LLC. Bridgewater, New Jersey (Amneal), is voluntarily recalling 4 lots (see table below) of Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5mL packaged in 80 mL, 150 ...

Please provide your email address to receive an email when new articles are posted on . Clinical response was noted in 47.6% of patients treated with oral vancomycin therapy for IBD associated with ...

The FDA on Monday granted approval to CutisPharma’s drug Firvanq to treat Clostridium difficile-associated diarrhea and Staphylococcus aureus-associated intestinal inflammation (enterocolitis). Here ...

BAUDETTE, Minn., June 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received FDA approval of its Prior Approval Supplement for Vancomycin ...